Overview of Business Performance

Target Attainment 2017

2017 Group targets:

Growth and Profitability

Target Attainment 2017

Target Attainment 2017 (chart)

1 Issued in February 2017
2 Issued in October 2017
3 Currency- and portfolio-adjusted

Economic Position of the Bayer Group

In 2017, the Bayer Group’s operational business was at the prior-year level. Sales increased by 1.5% on a currency- and portfolio-adjusted basis, while EBITDA before special items came in at the prior-year level despite negative currency effects. Pharmaceuticals once again posted sales and earnings increases that resulted primarily from the strong development of our key growth products Xarelto™, Eylea™, Xofigo™, Stivarga™ and Adempas™. Our Consumer Health business registered declining sales and earnings development, predominantly as a result of weak business development in the United States. At Crop Science, currency- and portfolio-adjusted sales and EBITDA before special items were down year on year. This development was attributable to an adjustment of inventories in the distribution channel in Brazil. Animal Health posted an increase in sales and significant growth in EBITDA before special items. Core earnings per share of the Bayer Group increased by 1.0% to €6.74. We met our adjusted Group forecast for the full year for sales. EBITDA before special items came in slightly below our expectations, while core earnings per share exceeded our expectations.

Compare to Last Year